Tocolytic effect of a selective FP receptor antagonist in rodent models reveals an innovative approach to the treatment of preterm labor

André Chollet*1, Enrico Gillio Tos2 and Rocco Cirillo2

Address: 1Merck Serono, Geneva, Switzerland and 2LCG-RBM, I-10010 Colleretto Giacosa, Turin, Italy

Email: André Chollet* - andre.chollet@merckserono.net

* Corresponding author

Abstract

Background: Management of preterm labor by tocolysis remains an unmet medical need. Prostaglandins play a major role in regulation of uterine activity and in molecular mechanisms of human labor and parturition. There is some circumstantial evidence that prostaglandin F2α by action through the prostaglandin receptor subtype FP is effective in key events during labor uterine contraction, rupture of membranes and cervical dilation. This role of FP is briefly reviewed. In this study, we tested the hypothesis that an orally active and selective FP antagonist may arrest labor and delay parturition in animal models.

Methods: We examined the effects of a small molecule selective antagonist of the FP receptor (AS604872) in inhibition of spontaneous uterine contraction in pregnant rat near term. We tested AS604872 for its ability to delay preterm birth in a mouse model in which the anti-progestin agent RU486 triggered parturition.

Results: By oral or intravenous dosing AS604872 reduced markedly and dose-dependently the spontaneous uterine contractions in late-term pregnant rats at gestational days 19–21. In pregnant mice, AS604872 delayed the preterm birth caused by RU486 administration. The effect was dose-dependent with a significant increase in the mean delivery time of 16 and 33 hours at oral doses of 30 mg/kg and 100 mg/kg, respectively, in the case of labor triggered at gestational day 14. In both models AS604872 appeared more effective than the β-agonist ritodrine.

Conclusion: The tocolytic activity displayed by a selective FP receptor antagonist supports a key role for the FP receptor in the pathophysiology of premature birth and demonstrates the therapeutic potential of an FP antagonist for the treatment of preterm labor cases in which uterine hyperactivity plays a dominant role.
Background

Preterm birth is a serious health problem that remains the major cause of perinatal mortality and morbidity [1]. Spontaneous preterm labor is the major cause of prematurity birth. Despite important advances in our understanding of the mechanism of human parturition and the pathophysiology of preterm labor, there has been very little progress in the prediction, prevention and therapeutic management of preterm labor. Preterm increase of uterine activity is the most common expression of preterm labor. Therefore, pharmacological interventions aimed at maintaining uterine quiescence have been given much attention for the pharmaceutical management of preterm labor [2]. Tocolytic agents arrest preterm labor and prolong pregnancy up to a few days at the most but often with adverse effects on women and without clear demonstration of improvement in neonatal outcome [3,4].

Prostaglandins play a major role during pregnancy and parturition in all studied species, including human. In particular prostaglandins are involved, directly or through modulation of other endocrine or paracrine factors, in the final common pathway of preparation, activation and stimulation of uterine tissues leading to onset of labour [5-9]. Levels of prostaglandins in uterine tissues vary in time and regionally under the control of their synthesis by cyclooxygenases isozymes COX-1 and COX-2 and specific prostaglandin synthases on one hand and their metabolism by prostaglandin dehydrogenase enzymes on the other hand. Prostaglandins exert their effects through at least nine G protein-coupled receptor subtypes EP1-4, IP, FP, TP, DP, CRTH2 or DP2, some of them (EP1, EP3, FP, TP) existing as multiple splice variants [10,11]. PGE2 has dual uterotonic effects by action through EP1 and EP3 but may also exert an uterorelaxant effect through EP2 and EP4.

Prostaglandin F2α (PGF2α) contracts the myometrium in vitro and in vivo through activation of FP. Activation of FP [12] in the human myometrium by PGF2α results in the elevation of intracellular calcium concentration, which, in turn, leads to contraction of the uterine smooth cell muscle [13]. FP receptor protein expression increases in the rat myometrium with advancing gestational age thus enhancing sensitivity of the myometrium to PGF2α contractile action [14]. Likewise, FP is expressed in term human myometrium [13,15,16]. PGF2α has been shown to induce up-regulation of matrix metalloproteinase MMP1, an enzyme that breaks down collagen in cervical fibroblasts leading to cervical ripening [17]. PGF2α upregulates MMP-2 and MMP-9 and downregulates their naturally-occurring inhibitor TIMP-1 in human term decidua, thus accelerating the breakdown of collagen and the rupture of membranes [18]. PGF2α potentiates cortisol production by stimulating the enzyme 11β-hydroxysteroid dehydroge-

nase 1. Cortisol increases prostaglandin synthesis and decreases prostaglandin metabolism in human chorion trophoblasts thus creating a feed-forward loop in fetal membranes that may contribute to preterm birth [19]. Taken together all these findings strongly suggest that blocking FP activation might be beneficial for the control of preterm labour. Potentially, a tocolytic agent based on selective FP antagonism may be devoid of the side effects that were observed in the clinic with COX-1 and COX-2 inhibitors [20,21]. To test this hypothesis we have evaluated the effect of a recently identified orally active, potent and highly selective small molecule antagonist of the FP receptor (AS604872) in two rodent models of uterine contraction and preterm labor.

Methods

Materials

AS604872 or (2S)-3-[[1,1'-biphenyl]-4-ylsulfonyl]-N-[(R)-phenyl(2-pyridinyl)methyl]-1,3-thiazolidine-2-carboxamide was chemically synthesized at the Serono Pharmaceutical Research Institute (Geneva, Switzerland). In all the in vivo experiments AS604872 was administered in NP3S (5% N-methylpyrolidone, 25% polyethylene glycol 200, 30% polyethylene glycol 400, 20% propylene glycol, 20% saline), while ritodrine was solubilized in saline.

In vivo experiments

All the in vivo experiments were performed according to the European Council Directive 86/609/EEC and the Italian Health Ministry guidelines for the care and use of experimental animals (decrree 116/92).

Uterine contraction model

Sprague Dawley CD (SD) BR non-pregnant (200–300 g) or late-term certified pregnant (19–21 gestation days; 350–400 g) female rats from Charles River, Calco, (Italy) were used. PGF2α- or oxytocin-induced uterine contractions in anaesthetized non-pregnant rats and spontaneous uterine contractions in anaesthetized late-term rats were all performed as described previously [22].

Mouse preterm parturition model

Time-mated, primigravid certified pregnant CD1 mice transferred from Charles River (Calco, Italy) to our animal facility at day 11 of gestation were used. Preterm labor was induced according to previous reports with some modifications [23,24]. In detail, pregnant mice at gestational day 14 or 17 were treated subcutaneously with RU486 (mifepristone) 2.5 mg/kg/5 ml at 1:00 PM. Randomly defined subgroups of animals (n = 8–10/dose) were then treated twice daily orally with AS604872 (10-30-100 mg/kg) or ritodrine (30–100 mg/kg), or the vehicle (NP3S or saline 5 ml/kg) for a total of 4 administrations (6 PM on the same day of RU486 treatment, 8 AM and 6 PM on the next
day and 8 AM on the day after). Each animal was checked for the occurrence of delivery starting from 18 hours after RU486 treatment, every three hours during the light phase, and every six hours during the dark phase. Delivery time was defined as the time of the first pup presence. The pups delivered were scored and classified as abortions, pups born alive and pups born dead. Since some of the pups may die during the time elapsing between our inspections, all the dead pups were controlled by the galenic hydrostatic pulmonary docimasy. The dead pups were dissected and a portion of the lung placed in water. Lung floating over the water indicated air content, and the ability of the pup to breathe after birth. The mean delivery time after RU486 was calculated based on the individual time of first pup delivery for each treatment.

Statistical analysis
All data are means ± SEM. Statistical analysis was performed by one-way ANOVA, followed by Tukey’s test. Statistics were performed using S-Plus2000 (MathSoft Inc., Seattle, Washington, USA) and significance assumed at the 5% level.

Results
The potent and selective FP antagonist AS604872 (Ki human FP, 35 nM; rat FP, 158 nM, mouse, FP 323 nM; selectivity vs EP2 50-fold and >1,000-fold vs other prostanoid receptors) reduced markedly and dose-dependently the spontaneous uterine contractions in late-term pregnant rats at gestational days (GD) 19–21 (Figure 1). Intravenous injection at the two highest doses (1 and 3 mg/kg/min for 10 min infusion corresponding to a total dose of 10 and 30 mg/kg, respectively) inhibited uterine contractility by about 37 and 53%, respectively. By oral dosing, AS604872 was also able to reduce the spontaneous uterine contractions by around 28% and 32% of the pre-dose value at doses of 30 and 60 mg/kg, respectively (Figure 1). The inhibiting effect by oral route peaked at about 30 min after administration and remained at a sustained level up to the end of the observation period of 3 h (data not shown). The intravenous administration of ritodrine decreased the spontaneous uterine motility by about 25% without a dose-dependent relationship, whereas a dose of 120 mg/kg oral route was ineffective (Figure 1).

Oral treatment with AS604872 delayed the preterm birth caused by RU486 (mifepristone) administration in pregnant mice at GD 14 or GD17. The effect was dose-dependent with a significant increase in the mean delivery time of 16 and 33 hours at doses of 30 mg/kg and 100 mg/kg, respectively, in the case of labor triggered at GD14 (Figure 2). The parturition retardation effect of AS604872 on labor induced at GD17 was less marked with a delay of 16 hours at 100 mg/kg (Figure 3). In this model AS604872 was more effective than ritodrine at GD17 whereas both compounds were comparable at GD14.

In the RU486 preterm parturition model, as an important consequence of the prolongation of gestation, some dams treated with AS604872 or ritodrine delivered viable pups (Figure 4). The proportion of live pups was higher in the GD17 than in the GD14 model. Remarkably, when labor was induced at GD17, 44% of the 100 mg/kg AS604872 treated animals delivered viable pups compared to only 11% in the group treated with 100 mg/kg ritodrine. All the other deliveries resulted in abortions.

Discussion
We have used a potent and selective small molecule antagonist of the FP receptor to decipher the role of this prostanoid receptor subtype in preterm labor and parturition. It was known that FP-deficient mice showed impaired parturition by lack of luteolysis and consequently absence of progesterone withdrawal, a necessary event to trigger labor in most animal species [25]. One key finding of our study was that blocking FP had also a clear effect on the myometrium through inhibition of uterotonic pathways in the pregnant rat model of uterine contractility. It is interesting to note that uterine activity was not fully abolished by treatment with AS604872, suggesting that other biochemical pathways are likely to be activated towards term and underlying the complex pathophysiology of preterm delivery. In the mouse parturition model, the induc-
tion of labor by the anti-progestin agent mifepristone (RU486) activates endocrine pathways and a drop in progesterone level characterized by the up-regulation of labor-associated proteins as seen in the case of idiopathic preterm labor. The FP antagonist AS604872 delayed parturition thus indicating that FP plays a central role in preterm labor of endocrine etiology. There was a trend towards better tocolytic efficacy of AS604872 at GD14 compared to GD17. This may suggest that other biochemical pathways to labor and parturition are activated at advanced gestational age. One key observation was the enhanced viability of pups delivered by mice treated with AS604872, thus underlying the beneficial effect of prolonging gestation. In both models, AS604872 was benchmarked against the β-mimetic ritodrine that has been commonly used as tocolytic agent. There was a clear trend towards superior activity for AS604872.

Our findings support recent reports that used a non-competitive, non-selective and injectable FP peptide antagonist in sheep and human myometrial strips [26,27].

**Conclusion**

The tocolytic activity displayed by the selective antagonist AS604872 supports a key role for the FP receptor in the pathophysiology of premature birth and demonstrates the therapeutic potential of an FP antagonist for the treatment of preterm labor cases in which uterine hyperactivity plays a dominant role.

**List of abbreviations**

FP, prostaglandin F2α receptor; COX-1, COX-2, cyclooxygenase 1 or 2; PGF2α, prostaglandin F2α; GD, gestation day; MMP, matrix metallo-proteinase; TIMP, tissue inhibitor of matrix metallo-proteinase.
**Competition interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

AC was involved in the study design, data analysis and interpretation, and drafted the manuscript. EGT performed the animal experiments and was involved in data collection, analysis and interpretation. RC was involved in the design of experiments, the data analysis and interpretation. All authors read and approved the final manuscript.

**Acknowledgements**

We thank Marc Missotten, Anna Quattrapone, Patrick Page, Matthias Schwarz, Alexander Scheer, Manuela Fabiano, Morena Celi, Federica Cimbri and Andrea Ciravolo for expert assistance and helpful discussions. The sponsorship of Serono, PerkinElmer and Ferring for covering publication costs is gratefully acknowledged. We also than the EU project SAFE (The Special Non-Invasive Advances in Fetal and Neonatal Evaluation Network, LSHB-CT-2004-503243) for financial support and organisation of the 2005 and 2006 Preterm Labour workshops.

This article has been published as part of BMC Pregnancy and Childbirth Volume 7 Supplement 1, 2007: Proceedings of the First and Second European Workshops on Preterm Labour of the Special Non-Invasive Advances in Fetal and Neonatal Evaluation (SAFE) Network of Excellence. The full contents of the supplement are available online at http://www.biomedcentral.com/1471-2393/7/S1.

**References**

1. Morrison JJ, Slattery MM: Preterm delivery. Lancet 2002, 360(9329):1489-1497.
2. Schwarz MK, Page P: Preterm labor: An overview of current and emerging therapeutics. Curr Med Chem 2003, 10:1441-1468.
3. Gyetvai K, Hannah ME, Hodnett ED, Ohlsson A: Tocolytics for preterm labor: A systematic review. Obstet Gynecol 1999, 94:869-877.
4. Berkman ND, Thorp JM Jr, Lohr KN, Carey TS, Hartmann KE, Gavin NL, et al.: Tocolytic treatment for the management of preterm labor: A review of the evidence. Am J Obstet Gynecol 2003, 188(5):1648-1659.
5. Challis JRG, Sloboda DM, Alfaidy N, Lye SJ, Gibb W, Patel FA, Whittle WL, Newnham JP: Prostaglandins and mechanisms of preterm birth. Reproduction 2002, 124:1-17.
6. Challis JRG, Matthews SG, Gibb W, Lye SJ: Endocrine and paracrine regulation of birth at term and preterm. Endocr Rev 2000, 21:14-35.
7. Olson DM: The promise of prostaglandins: Have they fulfilled their potential as therapeutic targets for the delay of preterm birth? J Soc Gynecol Investig 2005, 12:466-478.
8. Slater DM, Zervou S, Thornton S: Prostaglandins and prostanooid receptors in human pregnancy and parturition. J Soc Gynecol Investig 2002, 9:118-124.
9. Nathanielsz PW, Smith G, Wu W: Topographical specialization of prostaglandin function in late pregnancy and at parturition in the baboon. Prostaglandins, Leukot Essent Fatty Acids 2004, 70:199-206.
10. Coleman RA, Smith WL, Narumiya S: International Union of Pharmacology classification of prostanooid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994, 46:205-229.
11. Hata AN, Breyer RT: Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune regulation. Pharmacol Ther 2004, 103:147-166.
12. Abramovitz M, Boie Y, Nguyen T, Rushmore TH, Bayne MA, Metters KM, Slepetz DM, Grygorczyk R: Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem 1994, 269:2632-2636.
13. Senior J, Marshall K, Sangha R, Clayton JK: In vitro characterization of prostanooid receptors on human myometrium at term pregnancy. Br J Pharmacol 1993, 108:501-506.
14. Al-Matubsi HM, Eis ALW, Brodct-Eppley J, MacPhee DJ, Ley S, Myatt L: Expression & localization of the contractile prostaglandin F receptor in pregnant rat myometrium in late gestation, labor, postpartum. Br J Reprod Fertil 2001, 65:1029-1037.
15. Leonhardt A, Glaser A, Wegmann M, Hackenberg R, Nusing RM: Expression of prostaglandin receptors in human lower segment human myometrium. Prostaglandins, Leukot Essent Fatty Acids 2003, 69:307-313.
16. Grigby PL, Sooranna SR, Adu-Amankwa B, Fitzner B, Brokman DE, Johnson MR, Myatt L: Regional expression of prostaglandin E2 and F2alpha receptors in human myometrium, amnion and choriod decidua with advancing gestation and labor. Br J Reprod Fertil 2002, 75:297-305.
17. Yoshida M, Nagawa N, Itoh H, Yura S, Takemura M, Wada Y, Sato T, Itoh A, Fuji S: Prostaglandin F2alpha, cytokines and cyclic mechanical stretch augment matrix metalloproteinase-1 secretion from cultured human uterine cervical fibroblast cells. Mol Reprod Dev 2002, 68:681-687.
18. Ulug U, Goldman S, Ben-Shlomo I, Shalev E: Matrix metalloproteinase MMP-2 and MMP-9 and their inhibitor TIMP-1, in human term decidua and fetal membranes: the effect of progstaglandin F2alpha and indomethacin. Mol Hum Reprod 2001, 7:1187-1193.
19. Alfaidy N, Xiong ZG, Myatt L, Lye SJ, Macdonald JF, Challis JRG: Prostaglandin F2alpha potentiates cortisol production by stimulating 11beta-hydroxysteroid dehydrogenase 1: A novel feedback loop that may contribute to human labor. J Clin Endocrinol Metab 2001, 86:5583-5592.
20. Norton ME, Merrill J, Cooper B, Kuller JA, Clyman RI: Neonatal complications after the administration of indomethacin for preterm labor. New Engl J Med 1993, 329:1602-1607.
21. Peruzzi L, Gianoglio B, Porcellini MG, Coppo R: Neonatal end-stage renal failure associated with maternal ingestion of COX-1 selective inhibitor nimesulide as tocolytic. New Engl J Med 1999, 341:1615.
22. Cirillo R, Gillio Tos E, Schwarz MK, Quattrapone A, Scheer A, Missotten M, D’orbaris J, Nichols A, Borrelli F, Giacchetti C, Goloio L, Marinelli P, Thomas RJ, Chewillard C, Laurent F, Portet K, Barberis C, Chollet P: Pharmacology of (25Z, 45Z)2-(25)-2-hydroxy-2-phenylethyl)-4-(methoxyimino)-1[2’-methyl[1,1’-biphenyl]-4-yl]carboxyl-2- pyrroldinonecarboxamide, a new potent and selective non-peptide antagonist of the oxtocin receptor. J Pharmacol Exp Ther 2003, 306:253-261.
23. Dudley DJ, Branch DW, Edwin SS, Mitchell MD: Induction of preterm birth in mice by RU486. Biol Reprod 1996, 55:992-995.
24. Garfield RE, Gasc JM, Bauleau EE: Effects of the antiprogestosterone RU 486 on preterm birth in rat. Am J Obstet Gynecol 1987, 157:1281-1285.
25. Sugimoto Y, Yamasaki A, Segi E, Tsuobi K, Aze Y, Nishimura T, Oida H, Yoshida N, Tanaka T, Katsuyama M, Hasumoto K, Murata T, Hirata L, Ichikawa A, Narumiya S: Failure of parturition in mice lacking the prostaglandin F receptor. Science 1997, 277:681-683.
26. Hirst JJ, Parkington HC, Young IR, Palliser HK, Peri KG, Olson DM: Delay of preterm birth in sheep by THG1 113.31, a prostaglandin F2alpha receptor antagonist. Am J Obstet Gynecol 2003, 195:252-266.
27. Friel AM, O’Reilly MW, Sexton DJ, Morrison JJ: Specific PGF2alpha receptor (FP) antagonism and human uterine contractility in vitro. BJOG Int J Obstet Gynecol 2005, 112:1034-1042.